BUSINESSJul 30 · 06:24 UTCBLOOMBERG

Dr Reddy's CEO On Clogged Semaglutide Pipeline

Dr Reddy's CEO Erez Israeli anticipates strong performance in the second half of FY2026-27 after resolving semaglutide pipeline issues. He predicts intense competition in the semaglutide generics market, with over 20 companies vying for market share.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Dr Reddy'sorganizationErez Israelipersonsemaglutidetopicgenerics markettopicBloombergorganization

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSJul 24 · 02:24 UTC
U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns
BUSINESSMay 29 · 13:14 UTC
STAT+: Allogene CEO David Chang stepping down
HEALTHApr 12 · 15:02 UTC
GSK reports promising early results in ovarian and womb cancer drug trial
BUSINESSJul 27 · 13:49 UTC
STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive
HEALTHJul 8 · 07:41 UTC
India Fat-Loss Drug Sales Slow After Early Spike From Generics